Today: 11 June 2026
Gold price today: GLD slips after hours as CME margin hike adds to year-end volatility
31 December 2025
2 mins read

Gold price today: GLD slips after hours as CME margin hike adds to year-end volatility

NEW YORK, December 31, 2025, 17:30 ET — After-hours

  • GLD was down 0.6% in after-hours trade as spot gold edged lower late in the day.
  • CME set new metal margin requirements to take effect after Wednesday’s close, raising the cash collateral needed for futures positions.
  • Traders are looking to early-January U.S. jobs and inflation reports for fresh clues on the Fed’s 2026 path.

Gold-linked exchange-traded funds eased in U.S. after-hours trading on Wednesday as bullion drifted lower into the final hours of the year. SPDR Gold Shares (GLD) was down 0.6% at $396.31.

The late dip matters because gold has become one of 2025’s defining trades, and the last week has seen unusually sharp swings. A fresh increase in futures margin requirements — the cash collateral traders must post to hold leveraged positions — has added to the pressure.

Investors are also recalibrating interest-rate expectations after Federal Reserve minutes showed deep divisions over the latest cut, keeping the 2026 policy outlook in focus. That backdrop can move the dollar and yields, key drivers for gold because the metal does not pay interest.

Spot gold was quoted at $4,332 an ounce at 5:11 p.m. ET, down $13.66, or 0.32%, on the day, data from JM Bullion showed.

The market’s recent turbulence has been swift. Spot gold fell 4.5% on Monday to $4,330.79, then rebounded 0.8% on Tuesday to $4,364.70, Reuters reported.

Even with the year-end wobble, gold is up about 66% in 2025 — its steepest annual climb since 1979 — supported by U.S. rate cuts, central-bank buying, geopolitical risks and flows into bullion-backed ETFs, Reuters said.

CME Group said new performance bond requirements for metals would take effect after the close on Wednesday, following an earlier adjustment that took effect this week. Higher margins force traders to put up more cash and can trigger position-cutting when prices swing quickly.

The Fed minutes, covering the Dec. 9-10 meeting, showed some policymakers saw the rate-cut decision as “finely balanced,” with debate centered on inflation progress and signs of softer job growth. The minutes also pointed to a more cautious outlook, with new projections showing only one rate cut expected next year after the benchmark rate was lowered to a 3.5%-3.75% range. Reuters

Currency moves stayed in the frame. The dollar held its gains after the minutes but was still on course for its steepest annual drop in eight years, Reuters reported — a broader tailwind for gold over 2025.

Gold-related equities tracked the softer tone. Newmont was down about 2% and Agnico Eagle fell 1.4% in late trading, while the iShares Gold Trust (IAU) slipped 0.7%.

“The trade remains generally favourable,” Peter Grant, vice president and senior metals strategist at Zaner Metals, said on Tuesday as prices steadied after the prior day’s selloff. Reuters

The calendar now shifts quickly. Most markets will be closed on Jan. 1 for the New Year holiday, and Reuters said its precious-metals report will resume on Jan. 2.

Traders will then turn to early-January U.S. data, including the Labor Department’s December jobs report scheduled for Jan. 9 and the December consumer price index on Jan. 13, as the next major tests for rate expectations. The Fed’s next policy meeting is Jan. 27-28, with investors currently expecting rates to be left unchanged.

Stock Market Today

  • Ford Stock Down 6% Over Five Years Amid Strategic Shift
    June 11, 2026, 10:58 AM EDT. Ford's stock has fallen 6% over five years, significantly underperforming the S&P 500's 71% gain despite a recent 20% rally. The company exited costly electric vehicle (EV) programs, launching Ford Energy to produce lithium-ion phosphate batteries for energy storage through a partnership with China's CATL. Investors remain cautious, focusing on Ford's reliance on domestic sales of its F-Series gas-powered trucks, its longstanding best-seller. Ford's strategic pivot away from EVs, admitting Chinese EV competition risks, and modest international presence contribute to lingering investor skepticism about its long-term value.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading
Previous Story

Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop